Journal of Pathology and Translational Medicine

Wan-Seop Kim

9 Articles

Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP: Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-Kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim; J Pathol Transl Med. 2024;58(4):147-164. Published online January 10, 2024; DOI: https://doi.org/10.4132/jptm.2023.11.01

4,813 View
471 Download
1 Crossref

In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

Citations

Citations to this article as recorded by

Apport de la génomique dans la prise en charge des cancers
Étienne Rouleau, Lucie Karayan-Tapon, Marie-Dominique Galibert, Alexandre Harlé, Isabelle Soubeyran
Revue Francophone des Laboratoires.2025; 2025(568): 67. CrossRef

Establishing molecular pathology curriculum for pathology trainees and continued medical education: a collaborative work from the Molecular Pathology Study Group of the Korean Society of Pathologists: Jiwon Koh, Ha Young Park, Jeong Mo Bae, Jun Kang, Uiju Cho, Seung Eun Lee, Haeyoun Kang, Min Eui Hong, Jae Kyung Won, Youn-La Choi, Wan-Seop Kim, Ahwon Lee; J Pathol Transl Med. 2023;57(5):265-272. Published online September 15, 2023; DOI: https://doi.org/10.4132/jptm.2023.08.26

3,190 View
203 Download
1 Web of Science
1 Crossref

Abstract PDF

Background
The importance of molecular pathology tests has increased during the last decade, and there is a great need for efficient training of molecular pathology for pathology trainees and as continued medical education.
Methods
The Molecular Pathology Study Group of the Korean Society of Pathologists appointed a task force composed of experienced molecular pathologists to develop a refined educational curriculum of molecular pathology. A 3-day online educational session was held based on the newly established structure of learning objectives; the audience were asked to score their understanding of 22 selected learning objectives before and after the session to assess the effect of structured education.
Results
The structured objectives and goals of molecular pathology was established and posted as a web-based interface which can serve as a knowledge bank of molecular pathology. A total of 201 pathologists participated in the educational session. For all 22 learning objectives, the scores of self-reported understanding increased after educational session by 9.9 points on average (range, 6.6 to 17.0). The most effectively improved items were objectives from next-generation sequencing (NGS) section: ‘NGS library preparation and quality control’ (score increased from 51.8 to 68.8), ‘NGS interpretation of variants and reference database’ (score increased from 54.1 to 68.0), and ‘whole genome, whole exome, and targeted gene sequencing’ (score increased from 58.2 to 71.2). Qualitative responses regarding the adequacy of refined educational curriculum were collected, where favorable comments dominated.
Conclusions
Approach toward the education of molecular pathology was refined, which would greatly benefit the future trainees.

Citations

Citations to this article as recorded by

Presence of RB1 or Absence of LRP1B Mutation Predicts Poor Overall Survival in Patients with Gastric Neuroendocrine Carcinoma and Mixed Adenoneuroendocrine Carcinoma
In Hye Song, Bokyung Ahn, Young Soo Park, Deok Hoon Kim, Seung-Mo Hong
Cancer Research and Treatment.2025; 57(2): 492. CrossRef

Fatty acid synthetase expression in triple-negative breast cancer: Jin Hee Park, Hye Seung Han, So Dug Lim, Wook Youn Kim, Kyoung Sik Park, Young Bum Yoo, Seung Eun Lee, Wan-Seop Kim; J Pathol Transl Med. 2022;56(2):73-80. Published online January 21, 2022; DOI: https://doi.org/10.4132/jptm.2021.10.27

5,570 View
197 Download
8 Web of Science
8 Crossref

Abstract PDF

Background
Triple-negative breast cancer (TNBC) has a relatively poor prognosis. Research has identified potential metabolic targets, including fatty acid metabolism, in TNBC. The absence of effective target therapies for TNBC led to exploration of the role of fatty acid synthetase (FASN) as a potential target for TNBC therapy. Here, we analyzed the expression of FASN, a representative lipid metabolism–related protein, and investigated the association between FASN expression and Ki-67 and the programmed death ligand 1 (PD-L1) biomarkers in TNBC.
Methods
Immunohistochemical expression of FASN was analyzed in 166 patients with TNBC. For analytical purposes, patients with 0–1+ FASN staining were grouped as low-grade FASN and patients with 2–3+ FASN staining as high-grade FASN.
Results
FASN expression was observed in 47.1% of TNBC patients. Low and high expression of FASN was identified in 75.9% and 24.1%, respectively, and no statistically significant difference was found in T category, N category, American Joint Committee on Cancer stage, or recurrence rate between the low and high-FASN expression groups. Ki-67 proliferation level was significantly different between the low and high-FASN expression groups. FASN expression was significantly related to Ki-67 as the level increased. There was no significant difference in PD-L1 positivity between the low- and high-FASN expression groups.
Conclusions
We identified FASN expression in 166 TNBC patients. The Ki-67 proliferation index was positively correlated with FASN level, indicating higher proliferation activity as FASN increases. However, there was no statistical association with PD-L1 SP142, the currently FDA-approved assay, or FASN expression level.

Citations

Citations to this article as recorded by

Lipid metabolism involved in progression and drug resistance of breast cancer
Wenxiang Fu, Aijun Sun, Huijuan Dai
Genes & Diseases.2025; 12(4): 101376. CrossRef
Protein biomarkers for diagnosis of breast cancer
Emeka Eze Joshua Iweala, Doris Nnenna Amuji, Faith Chinasaokwu Nnaji
Scientific African.2024; 25: e02308. CrossRef
Microarray analysis points to LMNB1 and JUN as potential target genes for predicting metastasis promotion by etoposide in colorectal cancer
Jiafei Liu, Hongjie Yang, Peng Li, Yuanda Zhou, Zhichun Zhang, Qingsheng Zeng, Xipeng Zhang, Yi Sun
Scientific Reports.2024;[Epub] CrossRef
The signature of extracellular vesicles in hypoxic breast cancer and their therapeutic engineering
Baiheng Zhu, Kehao Xiang, Tanghua Li, Xin Li, Fujun Shi
Cell Communication and Signaling.2024;[Epub] CrossRef
NFYA promotes malignant behavior of triple-negative breast cancer in mice through the regulation of lipid metabolism
Nobuhiro Okada, Chihiro Ueki, Masahiro Shimazaki, Goki Tsujimoto, Susumu Kohno, Hayato Muranaka, Kiyotsugu Yoshikawa, Chiaki Takahashi
Communications Biology.2023;[Epub] CrossRef
Role of EGFR and FASN in breast cancer progression
Suchi Chaturvedi, Mainak Biswas, Sushabhan Sadhukhan, Avinash Sonawane
Journal of Cell Communication and Signaling.2023; 17(4): 1249. CrossRef
Bioinformatics Method Was Used to Analyze the Highly Expressed Gene FAM83A of Breast Cancer in Young Women
Yongzhe Tang, Hao Wang, Qi He, Yuanyuan Chen, Jie Wang, Fahd Abd Algalil
Applied Bionics and Biomechanics.2022; 2022: 1. CrossRef
NCAPH promotes proliferation as well as motility of breast cancer cells by activating the PI3K/AKT pathway
Ting Zhang, Peng Li, Wanying Guo, Qipeng Liu, Weiqiang Qiao, Miao Deng
Physiology International.2022;[Epub] CrossRef

Molecular Testing of Lung Cancers: Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee; J Pathol Transl Med. 2017;51(3):242-254. Published online April 21, 2017; DOI: https://doi.org/10.4132/jptm.2017.04.10

16,007 View
607 Download
27 Web of Science
27 Crossref

Abstract PDF

Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.

Citations

Citations to this article as recorded by

Association between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung cancer
Dülger Onur, Yaylım İlhan, Öz Büge
Indian Journal of Pathology and Microbiology.2025; 68(1): 36. CrossRef
Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes
Raquel Ramos, Conceição Souto Moura, Mariana Costa, Nuno Jorge Lamas, Renato Correia, Diogo Garcez, José Miguel Pereira, Carlos Sousa, Nuno Vale
Journal of Personalized Medicine.2024; 14(5): 446. CrossRef
Evolution of therapy for ALK-positive lung carcinomas: Application of third-generation ALK inhibitors in real clinical practice
A. F. Nasretdinov, A. V. Sultanbaev, Sh. I. Musin, K. V. Menshikov, R. T. Ayupov, A. A. Izmailov, G. A. Serebrennikov, V. E. Askarov, D. V. Feoktistov
Meditsinskiy sovet = Medical Council.2024; (10): 74. CrossRef
Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer
Dong-Won Kang, Sun-Kyeong Park, Sokbom Kang, Eui-Kyung Lee
Lung Cancer.2024; 197: 107970. CrossRef
miR-92a-3p regulates cisplatin-induced cancer cell death
Romain Larrue, Sandy Fellah, Nihad Boukrout, Corentin De Sousa, Julie Lemaire, Carolane Leboeuf, Marine Goujon, Michael Perrais, Bernard Mari, Christelle Cauffiez, Nicolas Pottier, Cynthia Van der Hauwaert
Cell Death & Disease.2023;[Epub] CrossRef
Diagnostic Approach of Lung Cancer: A Literature Review
Jesi Hana, Novia Nurul Faizah
Jurnal Respirasi.2023; 9(2): 141. CrossRef
Molecular Pathology of Lung Cancer
James J. Saller, Theresa A. Boyle
Cold Spring Harbor Perspectives in Medicine.2022; 12(3): a037812. CrossRef
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2022; 56(5): 249. CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
TM4SF4 and LRRK2 Are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis
Kyungsoo Jung, Joon-Seok Choi, Beom-Mo Koo, Yu Jin Kim, Ji-Young Song, Minjung Sung, Eun Sol Chang, Ka-Won Noh, Sungbin An, Mi-Sook Lee, Kyoung Song, Hannah Lee, Ryong Nam Kim, Young Kee Shin, Doo-Yi Oh, Yoon-La Choi
Cancer Research and Treatment.2021; 53(1): 9. CrossRef
The promises and challenges of early non‐small cell lung cancer detection: patient perceptions, low‐dose CT screening, bronchoscopy and biomarkers
Lukas Kalinke, Ricky Thakrar, Sam M. Janes
Molecular Oncology.2021; 15(10): 2544. CrossRef
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review
Anthony Yu, Eva Huang, Momoka Abe, Kang An, Sun-Kyeong Park, Chanhyun Park
Expert Review of Pharmacoeconomics & Outcomes Research.2021; 21(3): 381. CrossRef
The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC
Parth Shah, Jacob Sands, Nicola Normanno
Lung Cancer.2021; 160: 118. CrossRef
Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
OncoTargets and Therapy.2021; Volume 14: 4671. CrossRef
Treatment of Patients With Non–Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations
Melina E. Marmarelis, Corey J. Langer
Clinical Lung Cancer.2020; 21(5): 395. CrossRef
Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
Eunhyang Park, Hyo Sup Shim
Cancer Research and Treatment.2020; 52(2): 543. CrossRef
High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
Yuyin Xu, Heng Chang, Lijing Wu, Xin Zhang, Ling Zhang, Jing Zhang, Yuan Li, Lei Shen, Xiaoli Zhu, Xiaoyan Zhou, Qianming Bai
Experimental and Molecular Pathology.2020; 117: 104548. CrossRef
An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients
Jiacong Wei, Anna A. Rybczynska, Pei Meng, Martijn Terpstra, Ali Saber, Jantine Sietzema, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry. J.M. Groen, Anthonie van der Wekken, Anke van den Berg, Klaas Kok
Cancers.2020; 12(10): 2843. CrossRef
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
Alexander Gavralidis, Justin F. Gainor
The Cancer Journal.2020; 26(6): 517. CrossRef
Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors
Jasna Metovic, Luisella Righi, Luisa Delsedime, Marco Volante, Mauro Papotti
Acta Cytologica.2020; 64(1-2): 16. CrossRef
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer
Eun Kyung Kim, Kyung A. Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim
Clinical Lung Cancer.2019; 20(1): e123. CrossRef
PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
Jongmin Lee, Chan Kwon Park, Hyoung‐Kyu Yoon, Young Jo Sa, In Sook Woo, Hyo Rim Kim, Sue Youn Kim, Tae‐Jung Kim
Thoracic Cancer.2019; 10(1): 103. CrossRef
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
Yeon Bi Han, Hyun Jung Kwon, Soo Young Park, Eun-Sun Kim, Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2019; 53(2): 86. CrossRef
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
Pathmanathan Rajadurai, Phaik Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Ahmad Bustamam, Lye Mun Tho
Lung Cancer.2019; 136: 65. CrossRef
Somatic mutations and immune checkpoint biomarkers
Brielle A. Parris, Eloise Shaw, Brendan Pang, Richie Soong, Kwun Fong, Ross A. Soo
Respirology.2019; 24(3): 215. CrossRef
Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib
Anna Chalmers, Laura Cannon, Wallace Akerley
The Oncologist.2019; 24(7): 963. CrossRef
Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces
Jae Seok Lee, Eun Kyung Kim, Moonsik Kim, Hyo Sup Shim
Lung Cancer.2018; 123: 121. CrossRef

Characteristics of Cutaneous Lymphomas in Korea According to the New WHO-EORTC Classification: Report of a Nationwide Study: Jae Ho Han, Young-Hyeh Ko, Yun Kyung Kang, Wan-Seop Kim, Yoon Jung Kim, Insun Kim, Hyun-Jung Kim, Soo Kee Min, Chan-Kum Park, Chan-Sik Park, Bong-Kyung Shin, Woo Ick Yang, Young-Ha Oh, Jong Sil Lee, Juhie Lee, Tae Hui Lee, Hyekyung Lee, Ho Jung Lee, Yoon Kyung Jeon, Hee Jeong Cha, Yoo-Duk Choi, Chul Woo Kim; Korean J Pathol. 2014;48(2):126-132. Published online April 28, 2014; DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.2.126

8,953 View
117 Download
14 Crossref

Abstract PDF

Background

Previously, cutaneous lymphomas were classified according to either the European Organization for the Research and Treatment of Cancer (EORTC) or the World Health Organization (WHO) classification paradigms. The aim of this study was to determine the relative frequency of Korean cutaneous lymphoma according to the new WHO-EORTC classification system.

Methods

A total of 517 patients were recruited during a recent 5 year-period (2006-2010) from 21 institutes and classified according to the WHO-EORTC criteria.

Results

The patients included 298 males and 219 females, and the mean age at diagnosis was 49 years. The lesions preferentially affected the trunk area (40.2%). The most frequent subtypes in order of decreasing prevalence were mycosis fungoides (22.2%), peripheral T-cell lymphoma (17.2%), CD30+ T-cell lymphoproliferative disorder (13.7%), and extranodal natural killer/T (NK/T) cell lymphoma, nasal type (12.0%). Diffuse large B-cell lymphoma accounted for 11.2% of cases, half of which were secondary cutaneous involvement; other types of B-cell lymphoma accounted for less than 1% of cases.

Conclusions

In comparison with data from Western countries, this study revealed relatively lower rates of mycosis fungoides and B-cell lymphoma in Korean patients, as well as higher rates of subcutaneous panniculitis-like T-cell lymphoma and NK/T cell lymphoma.

Citations

Citations to this article as recorded by

Varied presentations of primary cutaneous lymphoma: A case series from a tertiary care center in South India
Baby Shana, Betsy Ambooken, Sunitha Balakrishnan, Asokan Neelakandan, Kidangazhiyathmana Ajithkumar
Indian Journal of Cancer.2024; 61(1): 172. CrossRef
A retrospective study of prognostic factors and treatment outcome in advanced-stage Mycosis Fungoides and Sezary Syndrome
Zhuo-fan Xu, Hongyun Chen, Yuehua Liu, Wei Zhang, Hongzhong Jin, Jie Liu
Hematology.2024;[Epub] CrossRef
Prevalence, clinical features, and survival outcome trends of 627 patients with primary cutaneous lymphoma over 29 years: a retrospective review from single tertiary center in Korea
Ik Jun Moon, Chong Hyun Won, Sung Eun Chang, Chan-Sik Park, Dok-Hyun Yoon, Si Yeol Song, Mi Woo Lee, Woo Jin Lee
Scientific Reports.2024;[Epub] CrossRef
The First Case of Acute Myeloid Leukemia With t(10;11)(p13;q21);PICALM-MLLT10 Rearrangement Presenting With Extensive Skin Involvement
Min-Seung Park, Hyun-Young Kim, Jae Joon Lee, Duck Cho, Chul Won Jung, Hee-Jin Kim, Sun-Hee Kim
Annals of Laboratory Medicine.2023; 43(3): 310. CrossRef
Recent advances on cutaneous lymphoma epidemiology
G. Dobos, M. Miladi, L. Michel, C. Ram-Wolff, M. Battistella, M. Bagot, A. de Masson
La Presse Médicale.2022; 51(1): 104108. CrossRef
Specific cutaneous infiltrates in patients with haematological neoplasms: a retrospective study with 49 patients
Rebeca Calado, Maria Relvas, Francisca Morgado, José Carlos Cardoso, Oscar Tellechea
Australasian Journal of Dermatology.2021;[Epub] CrossRef
Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients
Gabor Dobos, Anne Pohrt, Caroline Ram-Wolff, Céleste Lebbé, Jean-David Bouaziz, Maxime Battistella, Martine Bagot, Adèle de Masson
Cancers.2020; 12(10): 2921. CrossRef
Primary cutaneous lymphoma in Argentina: a report of a nationwide study of 416 patients
Alejandra Abeldaño, Paula Enz, Matias Maskin, Andrea B. Cervini, Natallia Torres, Ana C. Acosta, Marina Narbaitz, Silvia Vanzulli, Mirta Orentrajch, Marta A. Villareal, Maria L. Garcia Pazos, Mariana Arias, Evelyn A. Zambrano Franco, Maria I. Fontana, Rob
International Journal of Dermatology.2019; 58(4): 449. CrossRef
Post-thymic CD4 positive cytotoxic T cell infiltrates of the skin: A clinical and histomorphologic spectrum of the unique CD4 positive T cell of immunosenescence
Cynthia M. Magro, Luke C. Olson, Shabnam Momtahen
Annals of Diagnostic Pathology.2019; 38: 99. CrossRef
Cutaneous lymphomas in Taiwan: A review of 118 cases from a medical center in southern Taiwan
Chaw-Ning Lee, Chao-Kai Hsu, Kung-Chao Chang, Cheng-Lin Wu, Tsai-Yun Chen, Julia Yu-Yun Lee
Dermatologica Sinica.2018; 36(1): 16. CrossRef
Imaging analysis of superficial soft tissue lymphomas
In Sook Lee, You Seon Song, Seung Hyun Lee, Young Jin Choi, Sung Moon Lee
Clinical Imaging.2018; 49: 111. CrossRef
Epidemiologic, clinical and demographic features of primary cutaneous lymphomas in Castilla‐La Mancha, Spain: are we different?
C. Ramos‐Rodríguez, M. García‐Rojo, G. Romero‐Aguilera, M. García‐Arpa, L. González‐López, M.P. Sánchez‐Caminero, J. González‐García, M. Delgado‐Portela, M.P. Cortina‐De La Calle, M.F. Relea‐Calatayud, F. Martín‐Dávila, R. López‐Pérez, M. Ramos‐Rodríguez
Journal of the European Academy of Dermatology and Venereology.2018;[Epub] CrossRef
Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior
Mineui Hong, Taehee Lee, So Young Kang, Suk-Jin Kim, Wonseog Kim, Young-Hyeh Ko
Modern Pathology.2016; 29(5): 430. CrossRef
Cutaneous lymphoma: Kids are not just little people
Katalin Ferenczi, Hanspaul S. Makkar
Clinics in Dermatology.2016; 34(6): 749. CrossRef

Neuroendocrine Dysplasia Combined in a Tubular Adenoma of Rectum: A Case Report: So-Young Lee, Dae-Yong Hwang, Tae Sook Hwang, Wan-Seop Kim, So Dug Lim, Wook Youn Kim, Se-Hun Kim, Hye Seung Han; Korean J Pathol. 2013;47(5):495-498. Published online October 25, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.495

8,311 View
66 Download
4 Crossref

PDF

Citations

Citations to this article as recorded by

Neuroendocrine cell micronests of the colon
Richard R. Pacheco, Maria Faraz, Hwajeong Lee
Human Pathology Reports.2022; 28: 300644. CrossRef
Incidental morphological findings in colorectal adenomas
Parag D Dabir, Rachel S van der Post, Iris D Nagtegaal
Histopathology.2021; 78(3): 348. CrossRef
Large cell neuroendocrine tumor of the gastrointestinal tract with concurrent tubular adenomas
Inayat GILL, Christienne SHAMS, Elisa QUIROZ, Subhashree M. KRISHNAN, Susanna GAIKAZIAN
Gazzetta Medica Italiana Archivio per le Scienze Mediche.2021;[Epub] CrossRef
Neuroendocrine tumor mixed with adenoma in rectum: a case report and literature review
Jiancong Hu, Xiaochuan Chen, Dezheng Lin, Zhaoliang Yu, Juan Li, Xuefeng Guo
International Journal of Surgery Oncology.2019; 4(6): e79. CrossRef

Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group: Hyo Sup Shim, Jin-Haeng Chung, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Geon Kook Lee, Soon-Hee Jung, Se Jin Jang; Korean J Pathol. 2013;47(2):100-106. Published online April 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.100

10,904 View
93 Download
12 Crossref

Abstract PDF

Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Citations

Citations to this article as recorded by

Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer
Insu Kim, Hee Yun Seol, Soo Han Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop Eom
Cancers.2023; 15(5): 1445. CrossRef
Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
Dorine de Jong, Jeeban P. Das, Hong Ma, Jacienta Pailey Valiplackal, Conor Prendergast, Tina Roa, Brian Braumuller, Aileen Deng, Laurent Dercle, Randy Yeh, Mary M. Salvatore, Kathleen M. Capaccione
Cancers.2023; 15(10): 2855. CrossRef
Coordination games in cancer
Péter Bayer, Robert A. Gatenby, Patricia H. McDonald, Derek R. Duckett, Kateřina Staňková, Joel S. Brown, Jun Tanimoto
PLOS ONE.2022; 17(1): e0261578. CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy
Justin J Kuhlman, Muhamad Alhaj Moustafa, Liuyan Jiang, Han W Tun
Journal of Blood Medicine.2021; Volume 12: 833. CrossRef
Molecular Testing of Lung Cancers
Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
Journal of Pathology and Translational Medicine.2017; 51(3): 242. CrossRef
Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience
Choonhee Son, Eun‐Ju Kang, Mee Sook Roh
Diagnostic Cytopathology.2015; 43(7): 532. CrossRef
Ultrasonography-Guided Core Biopsy of Supraclavicular Lymph Nodes for Diagnosis of Metastasis and Identification of Epidermal Growth Factor Receptor (EGFR) Mutation in Advanced Lung Cancer
Jooae Choe, Mi Young Kim, Jung Hwan Baek, Chang-Min Choi, Hwa Jung Kim
Medicine.2015; 94(29): e1209. CrossRef
Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis
Amir Awwad, Sandeep Tiwari, Vishakha Sovani, David R Baldwin, Maruti Kumaran
BMJ Open Respiratory Research.2015; 2(1): e000075. CrossRef
Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non‐small‐cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage
Tae‐Jung Kim, Chan Kwon Park, Chang Dong Yeo, Kihoon Park, Chin Kook Rhee, Jusang Kim, Seung Joon Kim, Sang Haak Lee, Kyo‐Young Lee, Hyoung‐Kyu Yoon
Journal of Surgical Oncology.2014; 110(3): 245. CrossRef
Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry
An Na Seo, Tae-In Park, Yan Jin, Ping-Li Sun, Hyojin Kim, Hyun Chang, Jin-Haeng Chung
Lung Cancer.2014; 83(3): 316. CrossRef
Molecular Pathology of Lung Cancer: Current Status and Future Directions
Mee Sook Roh
Tuberculosis and Respiratory Diseases.2014; 77(2): 49. CrossRef

Interobserver Variability in Diagnosing High-Grade Neuroendocrine Carcinoma of the Lung and Comparing It with the Morphometric Analysis: Seung Yeon Ha, Joungho Han, Wan-Seop Kim, Byung Seong Suh, Mee Sook Roh; Korean J Pathol. 2012;46(1):42-47. Published online February 23, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.1.42

8,302 View
46 Download
20 Crossref

Abstract PDF

Background

Distinguishing small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung is difficult with little information about interobserver variability.

Methods

One hundred twenty-nine cases of resected SCLC and LCNEC were independently evaluated by four pathologists and classified according to the 2004 World Health Organization criteria. Agreement was regarded as "unanimous" if all four pathologists agreed on the classification. The kappa statistic was calculated to measure the degree of agreement between pathologists. We also measured cell size using image analysis, and receiver-operating-characteristic curve analysis was performed to evaluate cell size in predicting the diagnosis of high-grade neuroendocrine (NE) carcinomas in 66 cases.

Results

Unanimous agreement was achieved in 55.0% of 129 cases. The kappa values ranged from 0.35 to 0.81. Morphometric analysis reaffirmed that there was a continuous spectrum of cell size from SCLC to LCNEC and showed that tumors with cells falling in the middle size range were difficult to categorize and lacked unanimous agreement.

Conclusions

Our results provide an objective explanation for considerable interobserver variability in the diagnosis of high-grade pulmonary NE carcinomas. Further studies would need to define more stringent and objective definitions of cytologic and architectural characteristics to reliably distinguish between SCLC and LCNEC.

Citations

Citations to this article as recorded by

Case report: A patient with EGFR L861Q positive adenosquamous lung carcinoma transforming into large cell neuroendocrine cancer after treatment with Almonertinib
Kele Cheng, Yong Zhu, Ran Sang, Zhongsheng Kuang, Yang Cao
Frontiers in Oncology.2025;[Epub] CrossRef
Updates on lung neuroendocrine neoplasm classification
Giulia Vocino Trucco, Luisella Righi, Marco Volante, Mauro Papotti
Histopathology.2024; 84(1): 67. CrossRef
Recent advancement of HDAC inhibitors against breast cancer
Syed Abdulla Mehmood, Kantrol Kumar Sahu, Sounok Sengupta, Sangh Partap, Rajshekhar Karpoormath, Brajesh Kumar, Deepak Kumar
Medical Oncology.2023;[Epub] CrossRef
Genomic Feature of a Rare Case of Mix Small-Cell and Large-Cell Neuroendocrine Lung Carcinoma: A Case Report
Youcai Zhu, Feng Zhang, Dong Yu, Fang Wang, Manxiang Yin, Liangye Chen, Chun Xiao, Yueyan Huang, Feng Ding
Frontiers in Oncology.2022;[Epub] CrossRef
Small-Cell Carcinoma of the Lung: What We Learned about It?
Luisella Righi, Marco Volante, Mauro Papotti
Acta Cytologica.2022; 66(4): 257. CrossRef
Hierarchical identification of a transcriptional panel for the histological diagnosis of lung neuroendocrine tumors
Juxuan Zhang, Jiaxing Deng, Xiao Feng, Yilong Tan, Xin Li, Yixin Liu, Mengyue Li, Haitao Qi, Lefan Tang, Qingwei Meng, Haidan Yan, Lishuang Qi
Frontiers in Genetics.2022;[Epub] CrossRef
Immunohistochemical Staining With Neuroendocrine Markers is Essential in the Diagnosis of Neuroendocrine Neoplasms of the Esophagogastric Junction
Dea N.M. Jepsen, Anne-Marie K. Fiehn, Rajendra S. Garbyal, Ulla Engel, Jakob Holm, Birgitte Federspiel
Applied Immunohistochemistry & Molecular Morphology.2021; 29(6): 454. CrossRef
Improving differential diagnosis of pulmonary large cell neuroendocrine carcinoma and small cell lung cancer via a transcriptomic, biological pathway-based machine learning model
Junhong Guo, Likun Hou, Wei Zhang, Zhengwei Dong, Lei Zhang, Chunyan Wu
Translational Oncology.2021; 14(12): 101222. CrossRef
Are Neuroendocrine Negative Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma with WT RB1 two Faces of the Same Entity?
Dmitriy Sonkin, Anish Thomas, Beverly A Teicher
Lung Cancer Management.2019;[Epub] CrossRef
Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied
Alessandra Fabbri, Mara Cossa, Angelica Sonzogni, Mauro Papotti, Luisella Righi, Gaia Gatti, Patrick Maisonneuve, Barbara Valeri, Ugo Pastorino, Giuseppe Pelosi
Virchows Archiv.2017; 470(2): 153. CrossRef
The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases
Erik Thunnissen, Alain C. Borczuk, Douglas B. Flieder, Birgit Witte, Mary Beth Beasley, Jin-Haeng Chung, Sanja Dacic, Sylvie Lantuejoul, Prudence A. Russell, Michael den Bakker, Johan Botling, Elisabeth Brambilla, Erienne de Cuba, Kim R. Geisinger, Kenzo
Journal of Thoracic Oncology.2017; 12(2): 334. CrossRef
Reply to Letter “The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.”
Erik Thunnissen, Birgit I. Witte, Masayuki Noguchi, Yasushi Yatabe
Journal of Thoracic Oncology.2017; 12(6): e70. CrossRef
What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?
Giuseppe Pelosi, Alessandra Fabbri, Mara Cossa, Angelica Sonzogni, Barbara Valeri, Luisella Righi, Mauro Papotti
Seminars in Diagnostic Pathology.2015; 32(6): 469. CrossRef
Unraveling Tumor Grading and Genomic Landscape in Lung Neuroendocrine Tumors
Giuseppe Pelosi, Mauro Papotti, Guido Rindi, Aldo Scarpa
Endocrine Pathology.2014; 25(2): 151. CrossRef
Grading the neuroendocrine tumors of the lung: an evidence-based proposal
G Rindi, C Klersy, F Inzani, G Fellegara, L Ampollini, A Ardizzoni, N Campanini, P Carbognani, T M De Pas, D Galetta, P L Granone, L Righi, M Rusca, L Spaggiari, M Tiseo, G Viale, M Volante, M Papotti, G Pelosi
Endocrine-Related Cancer.2014; 21(1): 1. CrossRef
Controversial issues and new discoveries in lung neuroendocrine tumors
Giuseppe Pelosi, Kenzo Hiroshima, Mari Mino-Kenudson
Diagnostic Histopathology.2014; 20(10): 392. CrossRef
BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas
Muhammad F Bari, Helen Brown, Andrew G Nicholson, Keith M Kerr, John R Gosney, William A Wallace, Irshad Soomro, Salli Muller, Danielle Peat, Jonathan D Moore, Lesley A Ward, Maxim B Freidin, Eric Lim, Manu Vatish, David R J Snead
Histopathology.2014; 64(4): 547. CrossRef
Neuroendocrine tumours—challenges in the diagnosis and classification of pulmonary neuroendocrine tumours
M A den Bakker, F B J M Thunnissen
Journal of Clinical Pathology.2013; 66(10): 862. CrossRef
Morphologic Analysis of Pulmonary Neuroendocrine Tumors
Seung Seok Lee, Myunghee Kang, Seung Yeon Ha, Jungsuk An, Mee Sook Roh, Chang Won Ha, Jungho Han
Korean Journal of Pathology.2013; 47(1): 16. CrossRef
Altered expression of microRNA miR‐21, miR‐155, and let‐7a and their roles in pulmonary neuroendocrine tumors
Hyoun Wook Lee, Eun Hee Lee, Seung Yeon Ha, Chang Hun Lee, Hee Kyung Chang, Sunhee Chang, Kun Young Kwon, Il Seon Hwang, Mee Sook Roh, Jeong Wook Seo
Pathology International.2012; 62(9): 583. CrossRef

WITHDRAWN:A Clinicopathologic Study of 220 Cases of Pulmonary Sclerosing Pneumocytoma in Korea: A Nationwide Survey: Myunghee Kang, Seung Yeon Ha, Joung Ho Han, Mee Sook Roh, Se Jin Jang, Hee Jin Lee, Heae Surng Park, Geon Kook Lee, Kyo Young Lee, Jin-Haeng Chung, Yoo Duk Choi, Chang Hun Lee, Lucia Kim, Myoung Ja Chung, Soon Hee Jung, Gou Young Kim, Wan-Seop Kim; Received April 4, 2018 Accepted July 9, 2018 Published online July 16, 2018; DOI: https://doi.org/10.4132/jptm.2018.07.10 [Accepted]

5,310 View
63 Download

Author index